New research shows that hospital stays are the main cost of bipolar disorder to UK's NHS, accounting for 60% vs 7% for drugs

5 August 2010

In the UK, hospital stays for people with bipolar disorder cost taxpayers £207 million ($324.2 million) a year, according to the research sponsored by AstraZeneca presented yesterday. The National Health Service spends just 7% (£25 million) of the total costs for bipolar disorder on medicines versus 60% on hospital admissions. The findings of the research are important as the NHS has been told to identify £15-20 billion of cost savings by the end of the 2013-14 financial year.

The research was led by Allan Young in collaboration with AstraZeneca. Prof Young, formerly of Newcastle University and currently of the University of British Columbia, said of the research: "The main reason for hospitalizations in bipolar disorder is relapses suffered by patients in which they experience extreme mood changes. There is evidence to suggest that a range of available treatments for bipolar disorder are able to reduce the risk of patients

'Spend to save' approach of new administration

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical